|
gptkbp:instanceOf
|
gptkb:drug
long-acting beta2-adrenergic agonist
|
|
gptkbp:approvedBy
|
1998
|
|
gptkbp:ATCCode
|
gptkb:R03AC13
|
|
gptkbp:brand
|
gptkb:Foradil
gptkb:Oxeze
Perforomist
|
|
gptkbp:CASNumber
|
73573-87-2
|
|
gptkbp:category
|
sympathomimetic amine
bronchodilator
|
|
gptkbp:combines
|
gptkb:budesonide
gptkb:aclidinium
gptkb:mometasone
glycopyrronium
|
|
gptkbp:contraindication
|
hypersensitivity to formoterol
|
|
gptkbp:discoveredBy
|
gptkb:AstraZeneca
|
|
gptkbp:eliminationHalfLife
|
10 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C19H24N2O4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
formoterol
|
|
gptkbp:IUPACName
|
N-[2-hydroxy-5-[(1RS,2SR)-2-hydroxy-3-(hydroxymethylamino)propyl]phenyl]formamide
|
|
gptkbp:KEGGID
|
D04022
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
beta2-adrenergic receptor agonist
|
|
gptkbp:MedlinePlusID
|
a699063
|
|
gptkbp:meltingPoint
|
120-122°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
61-64%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201313
3083540
DB00983
|
|
gptkbp:routeOfAdministration
|
inhalation
|
|
gptkbp:sideEffect
|
headache
tremor
nervousness
palpitations
muscle cramps
|
|
gptkbp:synonym
|
gptkb:formoterol_fumarate
gptkb:eformoterol
|
|
gptkbp:UNII
|
BD5R679Q1B
|
|
gptkbp:usedFor
|
asthma
chronic obstructive pulmonary disease
|
|
gptkbp:bfsParent
|
gptkb:Foradil
|
|
gptkbp:bfsLayer
|
5
|